NCT06551857 The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
| NCT ID | NCT06551857 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Turku University Hospital |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-10-02 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-10-02 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.
Eligibility Criteria
Inclusion Criteria: * written informed consent * native Finnish speaker * age-normative hearing * for participants in the treatment arms: diagnosis of a malignancy that will be treated with curative intent with any of the following: 1) Cisplatin as the main chemotherapeutic agent, 2) oxaliplatin as the main chemotherapeutic agent, 3) cisplatin-based chemoradiation therapy in the head and neck region, 4) radiation therapy in the head and neck region Exclusion Criteria: * inability to provide written informed consent * Current or prior major otological condition that has affected or has had the potential to affect hearing * Conductive or asymmetric sensorineural HL of any severity * Severe sensorineural HL * Prior malignancy treated with chemotherapeutics or radiation therapy * Prior use of ototoxic medications * Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the trial, or may influence the result of the trial. * Any condition that, in the opinion of the investigator, would interfere with adherence to the trial requirements. For participants in the treatment arms: * Allergy or hypersensitivity to trial medications or their ingredients * Pregnancy or breast-feeding, aim of becoming pregnant during the trial.
Contact & Investigator
Tytti Willberg, PhD
PRINCIPAL INVESTIGATOR
Turku University Hospital
Frequently Asked Questions
Who can join the NCT06551857 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06551857 currently recruiting?
Yes, NCT06551857 is actively recruiting participants. Contact the research team at tytti.willberg@varha.fi for enrollment information.
Where is the NCT06551857 trial being conducted?
This trial is being conducted at Turku, Finland.
Who is sponsoring the NCT06551857 clinical trial?
NCT06551857 is sponsored by Turku University Hospital. The principal investigator is Tytti Willberg, PhD at Turku University Hospital. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.